Cell signaling molecules as drug targets in lung cancer: an overview

2011 ◽  
Vol 17 (4) ◽  
pp. 286-291 ◽  
Author(s):  
Tapan K Mukherjee ◽  
Karan Paul ◽  
Srirupa Mukhopadhyay
Keyword(s):  
Lung Cancer ◽  
Cell Signaling ◽  
Drug Targets ◽  
Signaling Molecules

Analysis of Amphotericin B-Induced Cell Signaling with Chemical Inhibitors of Signaling Molecules

2006 ◽  
Vol 50 (4) ◽  
pp. 337-347 ◽  
Author(s):  
Kenichiro Matsuo ◽  
Hitoshi Hotokezaka ◽  
Naoya Ohara ◽  
Yuji Fujimura ◽  
Atsutoshi Yoshimura ◽  
...  
Keyword(s):  
Cell Signaling ◽  
Amphotericin B ◽  
Signaling Molecules ◽  
Chemical Inhibitors

scholarly journals Ceramides and Cell Signaling Molecules in Psoriatic Epidermis: Reduced Levels of Ceramides, PKC-α, and JNK

2006 ◽  
Vol 21 (1) ◽  
pp. 95 ◽  
Author(s):  
Bark-Lynn Lew ◽  
Yunhi Cho ◽  
Jungmin Kim ◽  
Woo-Young Sim ◽  
Nack-In Kim
Keyword(s):  
Cell Signaling ◽  
Signaling Molecules

scholarly journals Targeting LIN28: a new hope in prostate cancer theranostics

2021 ◽  
Author(s):  
Garima Shrivastava ◽  
Alaa AA Aljabali ◽  
Seyed Hossein Shahcheraghi ◽  
Marzieh Lotfi ◽  
Madhur D Shastri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lung Cancer ◽  
Clinical Research ◽  
Recent Work ◽  
Drug Targets ◽  
Molecular Probes ◽  
Mortality And Morbidity ◽  
Remarkable Increase ◽  
Current Review ◽  
Cancer Theranostics

The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.

Stem Cell Signaling Molecules and Pathways

2017 ◽  
pp. 33-43
Author(s):  
Mirjana Pavlović ◽  
Ksenija Radotić
Keyword(s):  
Stem Cell ◽  
Cell Signaling ◽  
Signaling Molecules

scholarly journals Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer

Cancers ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 620 ◽  
Author(s):  
Connor O’Leary ◽  
Wen Xu ◽  
Nick Pavlakis ◽  
Derek Richard ◽  
Ken O’Byrne
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Drug Targets ◽  
Kinase Inhibitors ◽  
Therapeutic Option ◽  
Response Rates ◽  
Small Cell ◽  
Small Cell Lung ◽  
Asian Ethnicity

Identifying and targeting specific oncogenic drivers has become standard of care in the routine management of patients with lung cancer. Research is ongoing to expand the number of drug targets that can offer clinically meaningful outcomes. Rearranged during transfection (RET) fusions are the latest oncogenic driver alterations that show potential as a drug target. RET fusions occur in 1–2% of non-small cell lung cancer (NSCLC) cases. They are more commonly associated with younger age, female gender, non-smokers and Asian ethnicity. The RET kinase is abnormally activated through fusion with a partner protein such as KIF5B, CCDC6 or NCOA4. This leads to downstream intracellular signalling and enhancement of gene transcription and cell proliferation. The effectiveness of multi-kinase inhibitors in RET positive NSCLC has been explored in early phase and retrospective studies. From these studies, the most effective agents identified include cabozantanib and vandetanib. Overall response rates (ORR) vary from 18–47% across studies. In general, these agents have a manageable toxicity profile, although there are a number of off-target toxicities. Similar to the increased activity in ALK rearranged disease, pemetrexed has demonstrated superior response rates in this patient group and should be considered. Selective RET inhibitors, including LOXO-292 and BLU-667, are progressing in clinical trials. LOXO-292 has demonstrated an impressive ORR of 77% in RET positive solid tumours. It is anticipated this agent will be an effective targeted therapeutic option for patients with RET positive lung cancer.

Abstract B36: The role of the microRNA-200 family in the regulation of tumor cell signaling and metastasis in lung cancer

2015 ◽  
Author(s):  
Jonathon D. Roybal ◽  
David H. Peng ◽  
Christin Ungewiss ◽  
Pijus K. Mandal ◽  
John S. McMurray ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumor Cell ◽  
Cell Signaling

Scaffold Proteins and their Roles in Human Diseases

2020 ◽  
Vol 14 (01) ◽  
pp. 15-29
Author(s):  
Somsubhro Mukherjee ◽  
Boon Chuan Low
Keyword(s):  
Cell Signaling ◽  
Signaling Pathways ◽  
Drug Targets ◽  
Metabolic Diseases ◽  
Scaffold Proteins ◽  
Human Diseases ◽  
Normal Functions ◽  
Cellular Pathways ◽  
Cell Signaling Pathways

Scaffold proteins are critical regulators of important cell signaling pathways. Though scaffolds are not stringently defined in meaning, they are known to interact with numerous components of a signaling pathway, binding and bridging them into distinct and functional complexes. They control signal transduction and assist the localization of pathway components (organized in complexes) to definite regions of the cell such as the endosomes, plasma membrane, the cytoplasm, mitochondria, Golgi, and the nucleus. Years of research in this field have revealed the versatility of this class of protein and the important role it plays in maintaining the normal functions of the human body. Here, we discuss the role of several scaffold proteins which are implicated in important signaling pathways that play important roles in cardiac diseases, metabolic diseases, neurological disorders, and cancer. Their versatility and functions in human diseases make them attractive drug targets, several of which have been investigated in clinical trials. Future studies of scaffold proteins should give us an in-depth knowledge of how cell signaling works in normal and pathological conditions and would offer avenues to disrupt harmful cellular pathways to circumvent diseases.

RESEARCH FINDINGS

2012 ◽  
Vol 16 (02) ◽  
pp. 53-56
Keyword(s):  
Lung Cancer ◽  
Stem Cells ◽  
Smooth Muscle ◽  
Cancer Stem Cells ◽  
Drug Targets ◽  
Brain Cells ◽  
Skin Cells ◽  
Lung Cancer Stem Cells ◽  
Research Findings ◽  
Skin Samples

Researchers to Grow Smooth Muscle Cells from Patient Skin Cells. Singapore Scientists Identify Lung Cancer Stem Cells and New Drug Targets. T-rays Technology Could Help Develop Star Trek-Style Hand-held Medical Scanners. Human Brain Cells Created from Skin Samples.

Sign in / Sign up

Export Citation Format

Share Document